Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension
Open Access
- 23 November 2020
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 96 (4), e610-e618
- https://doi.org/10.1212/wnl.0000000000011207
Abstract
Objective To evaluate whether eculizumab helps patients with anti–acetylcholine receptor–positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. Methods Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. Results A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1–4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. Conclusion Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. ClinicalTrials.gov Identifier REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. Classification of Evidence This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo.Keywords
This publication has 13 references indexed in Scilit:
- Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre studyThe Lancet Neurology, 2017
- International consensus guidance for management of myasthenia gravisNeurology, 2016
- Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studiesKidney International, 2015
- Japanese clinical guidelines for myasthenia gravis: Putting into practiceClinical and Experimental Neuroimmunology, 2015
- Treatment-Refractory Myasthenia GravisJournal of Clinical Neuromuscular Disease, 2014
- Clinical characteristics of refractory myasthenia gravis patients.2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 2013
- Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuriaNature Biotechnology, 2007
- The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal HemoglobinuriaThe New England Journal of Medicine, 2006
- Myasthenia gravis: recommendations for clinical research standardsThe Annals of Thoracic Surgery, 2000